SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending higher after its Q2 earnings surpassed revenue and EPS estimates and substantially raised its future revenue guidance, igniting community discussions around its massive growth, strategic margin compression, and high short interest potentially leading to a squeeze.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after beating Q4 earnings expectations, yet its conservative Q1 guidance has sparked a "sell the news" reaction, leading to community debate on whether the dip is an overreaction given robust AI chip demand or a sign of stretched valuations and broader tech sector rotation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin Corp. is trending amid a sharp sell-off driven by market concerns over Google's Project Genie and new competition from CloudX in the ad tech sector. Community members largely view the reaction as overblown, highlighting the company's pure-play ad platform and upcoming earnings as potential catalysts for recovery.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst a significant sell-off, heavily influenced by the broader cryptocurrency market downturn, which impacts its substantial digital asset revenue. The community is sharply divided ahead of upcoming earnings, with some expressing deep concern over its valuation and crypto exposure, while others view the current dip as a compelling buying opportunity given Robinhood's diversification into new financial services.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after launching multi-cancer early detection testing through a partnership with GRAIL, expanding its proactive care offerings. Bulls are optimistic about this move into preventative healthcare as a significant growth catalyst, while some question the immediate revenue impact amid continued discussion of the stock's high short interest.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending after its Q4 earnings report sparked a volatile rebound, with community discussion centering on its robust revenue and record free cash flow as key strengths despite an initial negative reaction to its profit figures. Many perceive the stock as undervalued, fueling speculation about a potential short squeeze and its long-term strategy in autonomous vehicles.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending due to better-than-expected Q4 earnings and optimistic Q1 guidance, prompting multiple analyst upgrades and igniting community speculation of a short squeeze. This surge is also driven by discussions around new product launches like commercial microinverters and EV chargers, signaling a potential recovery in the solar sector.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point ahead of its upcoming earnings, with fervent speculation around a new hyperscaler data center contract following its significant Microsoft deal, though the community is divided on price action should a deal not materialize as expected.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending after reporting an earnings beat and confirming its AT&T fiber divestiture, though its stock is sharply down due to disappointing FY26 guidance. The community is divided, with some viewing it as a deep value opportunity given its AI infrastructure pivot and debt reduction, while others point to ongoing revenue challenges and perceived market manipulation.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is soaring after delivering Q4 earnings and a robust FY26 outlook that significantly surpassed estimates, driven by overwhelming demand for its obesity and diabetes drugs, Zepbound and Mounjaro. The community is actively discussing how Lilly's strong performance starkly contrasts with rival Novo Nordisk's recent weaker guidance, solidifying Lilly's perceived leadership in the rapidly expanding GLP-1 market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3% - Here's Why

Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3% - Still a Buy...

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Buy" from the sixteen ratings firms that are covering the company, MarketBeat reports. One research...

Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI

Campbell & CO Investment Adviser LLC raised its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 51.9% in the 3rd quarter, according to the company in its most recent filing with...

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up

DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.

3 Biotech Stocks With Major 2026 Catalysts

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have received an average rating of "Buy" from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. One...

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given an average recommendation of "Buy" by the sixteen ratings firms that are currently covering the firm, MarketBeat...

Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI

Marex Group plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the second quarter, according to the company in its most recent disclosure with the...

Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI

Camber Capital Management LP cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 68.0% in the second quarter, according to its most recent Form 13F filing with the Securities...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

Current Price	$21.36
Prev Close	$21.78
Open	$21.89
Dividend Yield	0.00%
50-Day Moving Average	$18.43
Beta	1.60
Avg. Volume	1.77M
PE Ratio	-7.48

52-Week High	$24.35
52-Week Low	$10.57
Market Capitalization	$3.4B
EPS (Annual)	-$2.57
Price to Book	3.45
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DNLI
Denali Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DNLI News

DNLIDenali Therapeutics Inc